Show simple item record

Phase I clinical and translational evaluation of AZD6738 in combination with durvalumab in patients (pts) with lung or head and neck carcinoma

dc.contributor.authorKrebs, Matthew G
dc.contributor.authorLopez, J
dc.contributor.authorEl-Khoueiry, A
dc.contributor.authorBang, Y
dc.contributor.authorPostel-Vinay, S
dc.contributor.authorAbidah, W
dc.contributor.authorIm, S
dc.contributor.authorKhoja, L
dc.contributor.authorStandifer, N
dc.contributor.authorJones, G
dc.contributor.authorMarco-Casanova, P
dc.contributor.authorFrewer, P
dc.contributor.authorBerges, A
dc.contributor.authorCheung, A
dc.contributor.authorStephens, C
dc.contributor.authorFelicetti, B
dc.contributor.authorDean, E
dc.contributor.authorPierce, A
dc.contributor.authorHollingsworth, S
dc.date.accessioned2019-04-29T09:49:01Z
dc.date.available2019-04-29T09:49:01Z
dc.date.issued2018en
dc.identifier.citationKrebs M, Lopez J, El-Khoueiry A, Bang YJ, Postel-Vinay S, Abidah W, et al. 413PD Phase I clinical and translational evaluation of AZD6738 in combination with durvalumab in patients (pts) with lung or head and neck carcinoma. Ann Oncol. 2018;29(suppl_8):135.en
dc.identifier.doi10.1093/annonc/mdy279.401en
dc.identifier.urihttp://hdl.handle.net/10541/621801
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdy279.401en
dc.titlePhase I clinical and translational evaluation of AZD6738 in combination with durvalumab in patients (pts) with lung or head and neck carcinomaen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentPhase I Unit, The Christie NHS Foundation Trust, Manchester, UKen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record